Latest Breaking News On - Institutional investors weigh in on rocket pharmaceuticals - Page 1 : comparemela.com

Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) Receives Average Recommendation of Moderate Buy from Brokerages

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price […]

United statesJohn militelloMark andrew whiteRocket pharmaceuticals incAllspring global investments holdingsTorray investment partnersRocket pharmaceuticals company profileAnalyst recommendations for rocket pharmaceuticalsJpmorgan chase coNews ratings for rocket pharmaceuticals dailyInstitutional investors weigh in on rocket pharmaceuticalsRocket pharmaceuticalsRocket pharmaceuticals stock performanceSecurities exchange commissionPrincipal financial group incNeedham company

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives New Coverage from Analysts at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $39.00 price target on the biotechnology company’s stock. RCKT has been the topic of several other reports. UBS Group cut their price objective […]

Kinnari patelGotham makkerJpmorgan chase coSteward partners investment advisoryAnalyst recommendations for rocket pharmaceuticalsWells fargo companyLife insurance coChina universal asset management coRocket pharmaceuticals incNeedham companyAdvisor group holdings incRocket pharmaceuticalsGoldman sachs groupRocket pharmaceuticals stock downInstitutional investors weigh in on rocket pharmaceuticalsNews ratings for rocket pharmaceuticals daily

Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) Receives $54 00 Average Price Target from Analysts

Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) Receives $54 00 Average Price Target from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Gotham makkerGaurav shahJpmorgan chase coRocket pharmaceuticals stock performanceRocket pharmaceuticals company profileCantor fitzgeraldRocket pharmaceuticalsInstitutional investors weigh in on rocket pharmaceuticalsNews ratings for rocket pharmaceuticals dailyGoldman sachs groupRocket pharmaceuticals incAnalyst recommendations for rocket pharmaceuticalsSynovus financial corpMetlife investment managementHightower advisorsGet free report

Brokerages Set Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) Target Price at $52 57

Brokerages Set Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) Target Price at $52 57
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Gotham makkerRocket pharmaceuticals company profileRocket pharmaceuticals stock performanceChina universal asset management coSteward partners investment advisoryRocket pharmaceuticalsSecurities exchange commissionRocket pharmaceuticals incWells fargo companyLife insurance coInstitutional investors weigh in on rocket pharmaceuticalsNews ratings for rocket pharmaceuticals dailyCantor fitzgeraldAdvisor group holdings incAnalyst recommendations for rocket pharmaceuticalsNeedham company

Lifesci Capital Reaffirms Outperform Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Lifesci Capital Reaffirms Outperform Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesGotham makkerStifel nicolausAsset management americas corpLife insurance coRocket pharmaceuticals incRocket pharmaceuticals company profileCantor fitzgeraldRocket pharmaceuticalsMetlife investment managementAnalyst recommendations for rocket pharmaceuticalsAllspring global investments holdingsInstitutional investors weigh in on rocket pharmaceuticalsNews ratings for rocket pharmaceuticals dailySecurities exchange commissionNeedham company